Karen Tubridy | Chief Operating Officer
Abcuro, Inc.

Karen Tubridy, PharmD is the Chief Operating Officer of Abcuro, Inc. Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. Karen has responsibility for the company operations including Program Development, Manufacturing, Quality, and early Commercial activities. Karen has over 30 years’ experience in drug development strategy and operations of novel and first-in-class therapeutics. Karen previously served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She had responsibility for driving global program strategies to IND/CTA and eventual global licensure and commercial launch including several rare disease drugs.

Appearances:

Day 2 - World Orphan Drug Congress USA 2025 @ 14:40

Panel: Rare Leadership: Women redefining healthcare

"Rare Leadership: Women Redefining Healthcare," assembles five distinguished leaders, four of which were featured on the Healthcare Marketing Sherpas Podcast: Rare Women Series, with host Janet Carlson, launched in April, 2025. Each of these women has and continues to pioneer change to improve healthcare and address critical rare disease and biopharma needs. They are united by a commitment to innovative therapies, patient-centered care, and sustainable healthcare solutions. Their backgrounds are diverse, with expertise in healthcare, biopharma, and biotech. They have unique perspectives on resolving rare disease challenges and improving healthcare for underserved communities. Their personal stories and professional insights will inspire others to shape the healthcare of tomorrow.

We’ll discuss: